Trials / Completed
CompletedNCT02297516
Safety and Efficacy of Azzalure/Dysport, Restylane/Emervel Filler and Restylane Skinbooster Treatment
An Evaluator-blinded Multi-center Study of Combined Treatment With Azzalure/Dysport, Restylane/Emervel Filler and Restylane Skinbooster as Compared to Single Treatment With Either Azzalure/Dysport Alone or Restylane/Emervel Filler Alone
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 35 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The efficacy and safety, as well as subject satisfaction will be evaluated after single treatment with Azzalure/Dysport alone or Restylane/Emervel filler alone followed by repeated combined treatment with Azzalure/Dysport, Restylane/Emervel filler and Restylane Skinbooster. Subjects will be followed for up to 18 months after initial treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Azzalure or Dysport | Glabellar lines |
| DEVICE | Restylane or Emervel filler | Facial tissue augmentation |
| DEVICE | Restylane Skinbooster | Facial skin rejuvenation |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2017-03-01
- Completion
- 2017-03-01
- First posted
- 2014-11-21
- Last updated
- 2022-10-14
- Results posted
- 2019-09-30
Locations
4 sites across 3 countries: Brazil, France, Sweden
Source: ClinicalTrials.gov record NCT02297516. Inclusion in this directory is not an endorsement.